Perth biotech Syngenis is deploying artificial intelligence to accelerate the discovery of RNA-based therapies, with the company aiming to reduce the time and cost involved in developing new drugs. Multiple outlets report that the push is focused on harnessing AI to streamline parts of the drug discovery process, particularly for RNA therapeutics. The coverage also frames the effort as part of a broader growth trend in RNA medicine, described as a fast-expanding global market that is influencing modern drug development.
While the articles share the same core details, they present the initiative with slightly different emphasis: some focus on RNA therapies specifically, while one report also mentions RNA diagnostics alongside therapeutics. Across the sources, the central common thread is Syngenis’s use of AI as a tool to increase efficiency in developing RNA-related medical products. The reports do not provide further specifics such as timelines, partnerships, or clinical milestones, focusing instead on the company’s strategy and the market context for RNA technologies.
